Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE:LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

  • The ICER released its report, giving evidence for the drug a “B+” rating and saying, “the evidence provides high certainty that tirzepatide delivers at least a small net health benefit when added to background therapy, with the possibility of a substantial net health benefit.”
  • However, ICER’s Jon Campbell, SVP for health economics, said that some uncertainty still exists.
  • “When compared to injectable semaglutide in one head-to-head trial, tirzepatide showed a greater decrease in HbA1c levels, weight, triglycerides, and blood pressure,” Campbell said in a statement. “However, studies of cardiovascular outcomes with tirzepatide have not been concluded, and therefore there is still uncertainty on its true comparative clinical effectiveness about other available treatment options.”
  • Related: Eli Lilly Shares Positive Tirzepatide Data At EASD Annual Meeting.
  • When ICER took a vote on clinical effectiveness, here’s what ended up happening:
  • A unanimous majority (13-0) found the evidence for tirzepatide is enough to demonstrate a net health benefit when tirzepatide added to background therapy is compared to background therapy alone.
  • A slight majority (7-6) found that the evidence is inadequate to demonstrate a net health benefit when tirzepatide added to background therapy is compared to injectable Novo Nordisk’s Ozempic (semaglutide). 
  • A majority (10-2 with 1 abstention) found that the evidence is insufficient to demonstrate a net health benefit when tirzepatide added to background therapy is compared to Boehringer Ingelheim’s Jardiance (empagliflozin).
  • The estimated annualized health benefit price benchmark range for tirzepatide is $5,500-$5,700 a year as per ICER. The Company predicted the drug price of around $4,643.50, based on injectable semaglutide.
  • Price Action: LLY shares are up 0.85% at $245.91 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.